

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED TWO PAGES.**

| NAME Kurtyka, Don E. | | POSITION TITLE Clinical Instructor, Hillsborough County Health Dept. Administrative Director, HIV Services | |
|--|---------------------------------|--|----------------------------|
| eRA COMMONS USER NAME | | | |
| EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) | | | |
| INSTITUTION AND LOCATION | DEGREE (if applicable) | YEAR(s) | FIELD OF STUDY |
| Fitchburg State College, Fitchburg, MA | BS | 1980 | Nursing |
| Western New England College, Springfield, MA | MBA | 1983 | Health Care Administration |
| University of South Florida, Tampa, Florida | Primary Care Nurse Practitioner | 1992 | Family Health Nursing |
| University of South Florida, Tampa, Florida | PhD | 2005-2006 completion | Nursing Science |

A. Positions and Honors.**Positions and Employment**

- 2004 - Body Health Resources Corporation, The Body: An AIDS and HIV Information Resource. Web-Site Moderator, "Ask the Expert: Fusion Inhibitors".
- 1994 - Administrative Director, HIV Services, Tampa General Hospital, Tampa, Florida
- 1995 - 1997 Nurse Practitioner, Men's Cancer Screening Clinic, Tampa General Hospital, Tampa, Florida.
- 1990 - 1993. Education Specialist, Center for Education, Research and Development, Tampa General Hospital, Tampa, Florida.
- 1988 - 1990 Assistant Director, Patient Services, Tampa General Hospital, Tampa, Florida.
- 1987 - 1988 Education Coordinator, Medical/Surgical Nursing, Tampa General Hospital, Tampa, Florida.
- 1994 - Administrative Director, HIV Services, Hillsborough County Health Department, Specialty Care Center, Tampa, Florida.
- 1993 - Advanced Registered Nurse Practitioner, Hillsborough County Health Department, Specialty Care Center, Tampa, Florida.
- 1994 - Instructor, University of South Florida, College of Medicine, Department of Internal Medicine, Division of Infectious and Tropical Diseases.
- 1994 - Faculty, Florida/Caribbean AIDS Education and Training Center, Tampa, Florida.
- 1993 - 1995 Adjunct Professor, University of South Florida, College of Arts and Sciences, Department of International Government Affairs, Tampa, Florida.
- 1993 - 1996 Adjunct Professor, University of Tampa, Department of Nursing, Tampa, Florida.
- 1986 - 1987 General Manager/ Director of Clinical Services, National Medical Care, Homecare Division, Waltham, Massachusetts.
- 1984 - 1986 Nurse Educator/Clinical Instructor, Ambulatory Care, Lahey Clinic Medical Center, Burlington, Massachusetts.
- 1984 - 1986 Nurse Clinician/Consultant, Home Nutritional Services/Healthdyne Company, Pine Brook, New Jersey.
- 1981 - 1984 Clinical Nurse III, Intravenous Therapy, Beth Israel Hospital, Boston, Massachusetts.

Other Experience and Professional Memberships

- 1992 - 1993 President, Sigma Theta Tau, International Nursing Honor Society, Delta Beta Chapter, University of South Florida, Tampa, Florida.
- 1996 - National Association of Nurses in AIDS Care.
- 1996 - Association of Nurses in AIDS Care, Tampa Bay Chapter.
- 1996 Co-chair, National Nursing AIDS Conference, Las Vegas, Nevada.
- 1997 - Tampa Bay Council of Advanced Practice Nurses, Tampa, Florida.
- 1997 - 1998 President, Association of Nurses in AIDS Care, Tampa Bay Chapter.
- 1998 - Member, Florida AIDS Drug Assistance Program Working Group, Tallahassee, Florida.

Principal Investigator/Program Director (Last, First, Middle):

- 1999 – 2000 Director-At-Large, Association of Nurses in AIDS Care, Tampa Bay Chapter.
- 1999 – 2001 Member, West Central Florida Ryan White Care Council, St. Petersburg, Florida.
- 1999 – Health Services Advisory Committee (Co-Chair), West Central Florida Ryan White Care Council, St. Petersburg, Florida.
- 2001 – Co-chair, Health Services Advisory Committee, West Central Florida Ryan White Care Council, St. Petersburg, Florida.
- 2002 - American Academy of HIV Medicine, Los Angeles, California.
- 2003 - Southern Nursing Research Society, Columbia, South Carolina,.
- 2003 - American Academy of Nurse Practitioners.
- 2003 President-Elect, Association of Nurses in AIDS Care, Tampa Bay Chapter.
- 2004 President, Association of Nurses in AIDS Care, Tampa Bay Chapter.
- 2005 Chair, Conference Committee, Association of Nurses in AIDS Care.

Awards and Honors

- 2004 Association of Nurses in AIDS Care (ANAC) Doctoral Nursing Fellowship.
- 2001 – 2002 Distinguished Lecturer, Association of Nurses in AIDS Care (ANAC).
- May 1998 Distinguished Service Award, Tampa General Healthcare Infectious Disease Center.
- 1991 President's Circle of Excellence Award, Tampa General Hospital.
- 1988- Sigma Theta Tau, International Nursing Honor Society.

B. Selected peer-reviewed publications (in chronological order).

1. Messmer P, Arnold J, **Kurtyka D**. Self Study Module for Mandatory AIDS Education, Nursing Economics, March/April 1990.
2. Ouellette D, **Kurtyka D**. Care of the Liver Transplant Patient, *Nurse*, Aug 1991.
3. **Kurtyka D**. A Protocol for Intravenous Therapy, *Nurse*, August/Sept 1992.
4. Messmer P, **Kurtyka D**, Kelley T. Theory-based Computer Training Program, *J of Nurs Staff Dev*, May/June 1992.
5. **Kurtyka D**. Advances in HIV/AIDS Care, *Nursing Spectrum*, Aug 1996.
6. **Kurtyka D**. Learn How to Prepare Patients for Safe and Healthy Travel, *Onc Nursing Soc Special Interest Group News* 10:3, Jan 2000, 3-6
7. **Kurtyka D**. The HIV-Positive Traveler, *Numedex.com*, 2002; 4:2, 89.

C. Research Support: Ongoing Research Support

1. Pfizer (Protocol A4001027/8) Nadler (PI) 3/24/2005-3/14/2006
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.
2. Pfizer (Protocol 1029) Nadler (PI) 3/25/2005-3/14/2006
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non-CCR5-Tropic HIV-1 Infected Subjects.
3. Tibotec (Protocol TMC 125-C211) Nadler (PI) 3/10/2005-3/6/2006
An Open-Label Trial of TMC125 in HIV-1 Infected Subjects Who Were Randomized to an Active Control Arm of Any Sponsor-Selected TMC125 Trial and Either Virologically Failed or Completed the Entire Treatment Period.
4. Incyte (Protocol RVT 901) Nadler (PI) 2/22/2005-2/14/2006
A Long-Term, Open Label, Non-Randomized Study to Evaluate the Safety of 100 and 200 mg Reverset (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Combination with Other Antiretroviral Agents.
5. Incyte (Protocol INCB 8721 RVT-203) Nadler (PI) 6/21/2004-4/3/2006

Principal Investigator/Program Director (Last, First, Middle):

A placebo-controlled, double-blind, parallel dose group study exploring the safety, tolerability, and virological effect of 50, 100, and 200mg Reverset™ (RVT) in HIV-infected antiretroviral therapy-experienced subjects when used in combination with other antiretroviral agents.

6. Tanox (Protocol 355.03) Nadler (PI) 5/13/2004-3/14/2006
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 with Optimized Background Therapy in Treatment-Experienced Subjects Infected with HIV-1.
7. Tibotec (Protocol TMC125-C223) Nadler (PI) 8/25/2004-6/13/2006
A Randomized, controlled, partially blinded phase IIb dose-finding trial of TMC 125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations.
8. Tibotec (Protocol TMC114-C202) Nadler (PI) 11/18/2003-10/11/2005
A Phase II Randomized, Controlled, Partially Blinded, 48-Week Trial to Investigate Dose Response of TMC114/RTV in 3 Class-Experienced HIV-1 Infected Subjects.
9. Boehringer Ingelheim (Protocol BIPI 1182.12) Nadler (PI) 4/17/2003-1/23/2006
Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir).
10. National Institute of Allergy and Infectious Diseases/NIH/DHHS Nadler (PI) 5/6/2003-1/26/2006
A Large Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) CPCRA
11. Pfizer/Agouron (Protocol A4311006) Nadler (PI) 4/8/2003-12/13/2005
A Phase 2, Randomized, Double-Blind, Dose-Ranging Study of Capravirine (AG1549) in Combination with Kaletra and at least 2 Nucleoside Reverse Transcriptase Inhibitors in HIV-infected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhibitors.
12. Boehringer Ingelheim (Protocol BI 1182.58) Nadler (PI) 10/30/2003-6/13/2006
An Open Label Study to Evaluate the Safety of Tipranavir plus Ritonavir When Used in Combination with Other Agents for the Treatment of Patients with HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options.
13. Boehringer Ingelheim (Protocol BI 1182.17) Nadler (PI) 6/12/2005-1/10/2006
A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects.
14. Johns Hopkins University (AHCPR) Nadler (PI) 2/23/2000-5/26/2006
Pilot Study for a Multisite HIV/AIDS Clinical and Resource Database.
15. Bristol-Myers Squibb. Nadler (PI) 12/13/2004-12/12/2005
Resistance Testing of HIV-Positive Patients Entering Therapy.
16. GlaxoSmithKline (APV 30005) Nadler (PI) 10/23/2001-3/27/2006
An Open-Label, Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects.
17. Merck (Protocol MRL 014) Nadler (PI) 5/28/2002-8/7/2005

Principal Investigator/Program Director (Last, First, Middle):

A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type 1 (HIV-1) gag Vaccine in HIV-1 Infected Individuals.

18. Nonsponsored Nadler (PI) 2/8/1999-6/13/2006
Collection and Preservation of Blood and Blood Component Specimens from HIV Infected Patients for Collaborative Studies

19. Hoffman La-Roche Nadler (PI) 1/29/2004-11/22/2005
Observational Cohort Study of Pneumonia in Fuzeon-Exposed and Non-Exposed Patients

CLOSED/COMPLETED STUDIES:

1. Hepatitis Resource Network – 005 Nadler (PI) 5/28/2002-3/8/2005
PEG-Interferon alpha2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon.

2. Pfizer/Agouron (Protocol A4311002) Nadler (PI) 8/8/2002-5/17/2004
A Double-Blind, Randomized, Placebo-Controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen.

3. Merck (Protocol 011-00) Nadler (PI) 2/1/2002-12/6/2005
A Study of the Safety, Tolerability, and Immunogenicity of HIV-1 gag DNA Formulated with CRL1005 Adjuvant Followed by the Adenovirus Serotype 5 HIV-1 gag Vaccine (Ad5 HIV-1 gag) in a Prime/Boost Regimen.

4. Boehringer Ingelheim (Protocol BI 1182.52) Nadler (PI) 5/10/2002-3/9/2004
Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted with Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects.

5. Bristol-Myers Squibb Nadler (PI) 10/28/2002-9/6/2004
ZEST-QD: A Phase IIIB, Open-Label, Randomized, Multicenter Study Switching HIV-1 Infected Subjects with a Viral Load of <50 Copies/ML on a Bid or More Frequent Initial Haart Regimen to a Once Daily Regimen Including Stavudine XR, Lamivudine, and Efavirenz